Trial reportEuropean journal of nuclear medicine and molecular imaging2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with
Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
11.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.European journal of cancer care · 2021Pooled it
- Efficacy and evaluation of dose-response relationship of selective internal radiation therapy for the management of liver metastases in neuroendocrine neoplasia.European journal of nuclear medicine and molecular imaging · 2026Trial
- Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).European journal of nuclear medicine and molecular imaging · 2024Trial
- Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.Radiology. Imaging cancer · 2022Trial
- Long-term toxicity of tandem radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy and safety of peptide radionuclide therapy withJournal of gastroenterology · 2026Observational
- Tumour Microenvironment-Informed Radiotheranostics: Why and How Nuclear Medicine Could Advance Precision Oncology in the Decade Ahead.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Global insights into [Scientific reports · 2026Article
- The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion.Advances in therapy · 2025Review
- Review
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors.European journal of nuclear medicine and molecular imaging · 2025Article
- PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.Journal of neuroendocrinology · 2025Article
- Imaging-derived biomarkers fromCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- M2 Macrophages-Based Immunotherapy: A New Therapeutic Approach in Liver Fibrosis.Advanced pharmaceutical bulletin · 2025Review
- Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.Journal of neuroendocrinology · 2025Review
- ASO Author Reflections: The Utility of PRRT upon Progression After Resection and Cytoreduction of GEP-NETs.Annals of surgical oncology · 2025Article
- Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases.Hematology/oncology clinics of North America · 2025Review
- Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors.Annals of surgical oncology · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 20 institutions in 11 countries.
Jonathan StrosbergGastrointestinal Department/Neuroendocrine Tumor Division, Moffitt Cancer Center, Tampa, FL, USA. jonathan.strosberg@moffitt.org.ORCID 0000-0001-8405-218X
Pamela L KunzDepartment of Medicine - Med/Oncology, Stanford University Medical Center, Stanford, CA, USA.
Andrew HendifarDepartment of Internal Medicine/Hematology/Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
James YaoDepartment of Gastrointestinal Medicinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David BushnellDepartment of Radiology, The University of Iowa, Iowa City, IA, USA.
Matthew H KulkeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Richard P BaumDepartment of Nuclear Medicine, Zentralklinik Bad Berka, Bad Berka, Germany.
Martyn CaplinDepartment of Gastroenterology and Tumour Neuroendocrinology, Royal Free Hospital, London, UK.
Philippe RuszniewskiDivision of Gastroenterology and Pancreatology, Hôpital Beaujon, Clichy, France.
Ebrahim DelpassandDepartment of Clinical Nuclear Medicine, Excel Diagnostics Imaging Clinic, Houston, TX, USA.
Timothy HobdayDepartment of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Chris VerslypeDepartment of Hepatology, University Hospitals and KU Leuven, Leuven, Belgium.
Al BensonHematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Rajaventhan SrirajaskanthanDepartment of Gastroenterology and General Internal Medicine, King's College Hospital - NHS Foundation Trust, London, UK.
Marianne PavelDivision of Hepatology and Gastroenterology, Charite-Universitätsmedizin Berlin, Berlin, Germany.
Jaume MoraDepartment of Nuclear Medicine, Hospital Universitari de Bellvitge, Barcelona, Spain.
Jordan BerlinDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Enrique GrandeDepartment of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain.
Nicholas ReedDepartment of Medical Oncology, Beatson Oncology Centre, Glasgow, UK.
Ettore SeregniDepartment of Nuclear Medicine Therapy and Endocrinology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Giovanni PaganelliDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Stefano SeveriDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Michael MorseDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
David C MetzGI Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Catherine AnsquerNuclear Medicine Department, Hôtel Dieu, University Hospital, Nantes, France.
Frédéric CourbonMedical Imaging, Oncology University Institut Claudius Regaud, Toulouse, France.
Adil Al-NahhasDivision of Imaging and Interventional Radiology, Imperial College London, London, UK.
Eric BaudinDepartment of Endocrine Oncology and Nuclear Medicine, Institut Gustave Roussy, Villejuif, France.
Francesco GiammarileDepartment of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
David TaïebDepartment of Nuclear Medicine, Hôpital de la Timone, Marseille, France.
Erik MittraDepartment of Nuclear Medicine, Oregon Health & Science University, Portland, OR, USA.
Edward WolinDepartment of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Thomas M O'DorisioDepartment of Internal Medicine, The University of Iowa, Iowa City, IA, USA.
Rachida LebtahiDepartment of Nuclear Medicine, Royal Free Hospital, London, UK.
Christophe M DerooseNuclear Medicine Department, University Hospitals and KU Leuven, Leuven, Belgium.
Chiara M GranaDivision of Nuclear Medicine, Istituto Europeo di Oncologia, Milan, Italy.
Lisa BodeiDepartment of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kjell ÖbergDepartment of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.
Berna Degirmenci PolackDepartment of Medical Information, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Beilei HeAdvanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Maurizio F MarianiResearch and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Germo GerickeResearch and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Paola SantoroDepartment of Clinical Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Jack L ErionAdvanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Laura RavasiResearch and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Eric KrenningDepartment of Nuclear Medicine, Cyclotron Rotterdam BV, Erasmus University Medical Center, Rotterdam, Netherlands.
NETTER-1 study group
Novartis (Switzerland) · CHUniversity of Iowa · USIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITBeatson West of Scotland Cancer Centre · GBBellvitge University Hospital · ESCedars-Sinai Medical Center · USHôpital Beaujon · FRHospital of the University of Pennsylvania · USInstitut Claudius Regaud · FRInternational Atomic Energy Agency · ATKing's College Hospital NHS Foundation Trust · GBMayo Clinic · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USOregon Health & Science University · USThe Royal Free Hospital · GBErasmus MC · NLEuropean Institute of Oncology · ITInstitut Gustave Roussy · FRMD Anderson Cancer Center Madrid · ES
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MProject 4: New Approaches to Improving the Effectiveness of Radionuclide Targeted Treatments in Neuroendocrine TumorsP50CA174521 · NCI · UNIVERSITY OF IOWA · PI ODORISIO, THOMAS · 2015 to 2021
$13.2MAdvanced Accelerator Applications, a Novartis Company N/ANCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA174521
Abstract
purposeTo assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with
methodsIn the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression.
resultsSignificantly prolonged median PFS occurred with
conclusions
Indexed as
Liver NeoplasmsNeuroendocrine TumorsOrganometallic CompoundsAlkaline PhosphataseHumansOctreotideTreatment OutcomeAlkaline PhosphataseOctreotideOrganometallic Compounds177Lu-DotatateLiver tumour burdenNETTER-1Neuroendocrine tumourOctreotide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.